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Introduction
Lung cancer is the leading cause of cancer-related mortality around the world [1, 2] . Lung cancer killed about 1.5 million people in 2010, and lung cancer has an extremely poor prognosis, with an overall 5 year survival of 16% in the USA and less than 10% in the UK [3] .
In China, the cigarette smoking rate increased dramatically during the past 2 decades, and the lung cancer mortality has increased by 465% during the past 30 years. Not surprisingly, lung cancer has become the main cause of death in urbanites and the second leading cause of death in rural population after liver cancer [4] . Non-small cell lung cancer (NSCLC) comprises adenocarcinoma and squamous cell carcinoma. In the past decade the overall survival rate of NSCLC patients is11% approximately [5] . Thus, a deep understanding of the pathogenesis of NSCLC development and progression is urgently needed.
MicroRNAs (miRNAs) are a group of non-coding, small (approximately 22 nucleotides in length) RNAs, which suppress protein expression by inhibiting translation or inducing mRNA degradation by binding to the 3'-untranslational region (3'UTR) of targeted mRNAs [6] . Beyond their involvement in diverse biological processes, it has been amply demonstrated that deregulation or dysfunction of miRNAs contribute to cancer development [7] . Regarding NSCLC, accumulated data showed that specific miRNAs profiles may predict prognosis and disease recurrence in early-stage NSCLC [8] [9] [10] [11] [12] .
MiR-4500 was identified, and its sequence was determined [13, 14] ; however, the function of miR-4500 remains unknown. Previously, we firstly predicted the potential target of miR-4500 by using a bioinformatic algorithm. The data indicated that miR-4500 may target the genes LIN28B and NRAS. Recent data indicate that LIN28B promotes growth and tumorigenesis of the intestinal epithelium via Let-7 [15] . NRAS is among the common oncogenes in human cancer [16] [17] [18] , and was initially identified in human neuroblastoma cells [19] . Secondly, we assayed the miR-4500 expression in NSCLC cells and found a low expression in NSCLC cells. Thus we conjectured that miR-4500 may play an important role in the pathogenesis of NSCLC.
Here we tried to prove the role of miR-4500 in NSCLC by investigating NSCLC patient survival and regulating its expression level in in vitro experiments. We found that downregulation of miR-4500 promoted NSCLC growth and identified its targeted genes. We hope our finding may elucidate the role of miR-4500 and provided a potential therapy target for NSCLC.
Materials and Methods

Patients
Surgical specimens from 70 NSCLC patients and matched control adjacent normal tissues were obtained postoperatively in 2009 from the Jinling Hospital, Nanjing University School of Medicine. Informed consent was obtained from each patient and the study was approved by the Ethics Committee of Nanjing University, Nanjing, China. All diagnoses were based on pathological and/or cytological evidence. Tissues were obtained before chemotherapy and radiotherapy and were immediately frozen and stored at −80 °C prior to qRT-PCR assay.
Cell culture and transfection
The human normal lung fibroblast cell line MRC-5, and the human NSCLC cell lines (SPC-A-1, LTEP-A-2, SK-MES-1, A549 and H1299), and HEK293 were obtained from the Cell Bank of Chinese Academy of Science (Shanghai, China). These cell lines were maintained in RPMI1640 (Invitrogen, Carlsbad, CA, USA) in the presence of 10% heat-inactivated fetal bovine serum, 100 IU/ml penicillin and 100 l g/ml streptomycin in a humidified 5% (v/v) atmosphere of CO2 at 37 °C. Transfections were performed using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocol. The efficiency of transfection was evaluated by assay of miR-4500 level.
RNA extraction and Real time q-PCR
RNA was extracted with Trizol reagent (Invitrogen) according to the manufacturer's protocol. The cDNA synthesis and real-time qPCR were subsequently performed using the Qiagen system as described detail in previous studies [20] . Real-time quantitative PCR analysis was performed using standard protocols using an Applied Biosystems 7500 HT sequence Detection System. The miR-4500 expression was assessed −ΔΔCt method. The primers used are as follows: GAPDH (5'-CCATGTTCGTCATGGGTGTGAACCA-3' and 5'-GCCAGTAGAGGCAGGGATGATGTTG-3') and LIN28B (5'-CTCTCCCTCGAGAAGTGGGA-3' and 5'-CAGACTCAGGCTCTCTCCCT-3'); NRAS (5'-CCAAATGAAGGTCACACTA -3' and 5'-AGAGACAGGATCAGGTCAGC -3').
MTT assay
For the MTT assay, 500 cells per well were seeded, in triplicate, in a 96-well plate with complete growth medium. Cells were counted over 3 days using the MTT assay (Promega, Fitchburg, WI, USA) as previously described [21] [22] [23] . The data were measured by Microtiter plate reader with a 570-nm filters (Promega).
Apoptosis assay
Cells were labeled with Annexin V-FITC and propidium iodide (PI) using an apoptosis detecting kit (Invitrogen, Canada) following the manufacturer's instructions. Then samples were subjected to FACS analysis (Becton Dickinson, San Jose, CA, USA) [24] .
MicroRNAs targets prediction
TargetScanHuman (http://www.targetscan.org/vert_61/) [25] [26] [27] [28] was applied to identify the potential target of miR-3928.
The miRNAs mimics, the miRNAs antisense oligonucleotides and the overexpression plasmids
The miRNAs mimics and the miRNAs antisense oligonucleotides (ASO) were obtained from GenePharma (GenePharma, Shanghai, China). The miRNAs mimics, and the negative control (NC) were transfected into the cells at a concentration of 50nM using the Lipofectamine 2000 (Invitrogen, Canada) transfection reagent according to the manufacturer's instructions. Cells were collected 48h or 72h later for further experiments. The overexpression plasmids, pcDNA3.1-LIN28B and pcDNA3.1-NRAS, were constructed and confirmed by the Shengong Company (Shanghai, China).
3'UTR reporter analysis
The LIN28B and NRAS 3'UTR reporter plasmids (pRL-LIN28B and pRL-NRAS) were constructed by the Shengong Company (Shanghai). Mutations in the miR-4500 seed regions of the LIN28B 3'UTR were generated using QuikChang Multi site -directed mutagenesis kit (Stratagene, Shanghai, China). The RL reporter plasmids (3.6fmol) and the pGL3-control (500ng for normalization; Promega) were transfected with Lipofectamine 2000 (Invitrogen) into A549 or H1299 cells (6×10 4 cells per well). Cells were collected after 48h for assaying using the Dual Luciferase reporter assay system (Promega) [29] .
Statistical Analysis
Data are presented as the mean ± s.d. from at least three independent experiments. The difference between groups were analyzed using the two-tailed Student's t test when only two groups were compared. The difference between groups were analyzed using the ANOVA test when three or more groups were compared. Correlation analysis was performed by two-tailed Person's correlation coefficient analysis. Patients survival was determined by Kaplan-Meier analysis. Statistical analyses were performed using the SPSS software version 17.0 (IBM Corporation, Armonk, NY, USA). P<0.05 was considered significantly different.
Results
Low expression of miR-4500 in NSCLC
To identify the role of miR-4500 in NSCLC, the miR-4500 expression level was assayed in normal lung tissues, human normal lung fibroblast cell line (MRC-5) and NSCLC cell lines. We found that miR-4500 expression in all NSCLC cell lines, especially in A549 and H1299, was lower than in normal lung and the normal lung fibroblast cell line (Fig. 1A) . Next, the general Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry expression of miR-4500 in NSCLC tissue samples from 70 NSCLC patients was compared with matched normal adjacent lung tissue samples; the qRT-PCR analysis showed the mean expression of miR-4500 in NSCLC tissue samples was lower than in normal adjacent lung tissue samples (Fig. 1B) . The analyses of 70 pairs of NSCLC tumor tissue samples and their matched normal adjacent tissue samples revealed that in 56 pairs, the expression of miR-4500 in NSCLC was lower in the NSCLC tumor samples than in the matched normal adjacent tissue samples; and in the other 14 pairs, the expression of miR-4500 was higher in the NSCLC tumor tissue samples than in the matched normal adjacent tissue samples (Fig. 1C) . These data above indicated that low expression of miR-4500 may promoted NSCLC. Kaplan-Meier curves of 70 patients with high or low miR-4500 expression. Seventy NSCLC patients were followed-up for 30 months, and deceased cases were recorded. Kaplan-Meier curves were drawn according to the miR-4500 expression. Expression of miR-4500 was assayed by qRT-PCR, and the mean value of all 70 cases was chosen as the cutoff point for separating miR-4500 high expression from miR-4500 low expression NSCLC cases.
(B). The miR-4500 expression in tumor tissues and in adjacent normal tissues were assayed by qRT-PCR. The difference of miR-4500 expression between the tumor tissue samples and in adjacent normal tissue samples in each patient was compared (C). *P<0.05.
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High miR-4500 expression was correlated with high patient survival rate
To reveal the role of miR-4500 in the NSCLC patient survival, overall survival analysis was implemented. Seventy NSCLC patients were followed up for 30 months, and no case was dropped. During the 30 months follow-up period, 53 out of 70 (76%) patients were deceased. The Kaplan-Meier curves showed that the patients with high miR-4500 expression (N=20) had a significantly higher survival (p<0.05) rate than those with low miR-4500 expression (N=50) (Fig. 2) .
MiR-4500 overexpression inhibited NSCLC cells proliferation and induced apoptosis
To investigate the role of miR-4500 in NSCLC cells proliferation, the cell lines A549 and H1299 were chosen for in vitro cell proliferation analyses, as A549 and H1299 showed a lower miR-4500 level than other NSCLC cell line. We firstly over-expressed the miR-4500 in the A549 and H1299 cells by transfection with miR-4500 mimics. The miR-4500 level was assayed by qRT-PCR 48h or 72h later (Fig. 3A) . Subsequently, cell proliferation was analyzed by the MTT assay. We found that overexpression of miR-4500 inhibited the A549 and H1299 cells proliferation (Fig. 3B) . Next, we assayed the cells apoptosis rate after miR-4500 upregulation, we found miR-4500 overexpression resulted in higher apoptosis rate in both of the NSCLC cell lines (Fig. 3C) . 
Down-regulation of miR-4500 promoted NSCLC proliferation and inhibited apoptosis
We down-regulated the expression of miR-4500 by transfecting miR-4500 ASO into the human normal lung fibroblast cell line (MRC-5). The miR-4500 level in MRC-5 cells was reduced 48 h after the transfection (Fig. 4A) . Next, the cells proliferation was analyzed by the MTT assay; the results showed that transfection with miR-4500 ASO promoted MRC-5 cells proliferation compared with cells transfected with miR-NC ASO (Fig. 4B) . Evaluation of cell apoptosis by FACS analysis revealed that miR-4500 down-regulation resulted in a lower apoptosis rate in MRC-5 (Fig. 4C) .
miR-4500 targeted LIN28B and NRAS
To investigate the mechanism involved in miR-4500-mediated effects in NSCLC, the miR-4500 potential target genes were predicted by a bioinformatics algorithm. Numerous genes were predicted (some of the predicted genes are shown in Fig. 5A ). Based on their potential relevance to NSCLC, LIN28B and NRAS were chosen for further study. Firstly, the 3'UTR of LIN28B and NRAS were mutated (Fig. 5A) , and then the 3'UTR of the two genes were cloned into luciferase reporter plasmids. Lastly, the miR-4500 and the reporter plasmids were cotransfected into HEK293 cells. Our data showed that the 3'UTRs of LIN28B and NRAS were targeted by miR-4500 (Fig. 5B) . We next examined the correlation between the level of miR-4500 and the expression of LIN28B and NRAS in the NSCLC tissue samples. Pearson's correlation coefficient analysis revealed that miR-4500 level was inversely correlated with LIN28B and NRAS expression in the NSCLC tissue samples analyzed (Fig. 5C) . Moreover, the MTT assay data showed that in both cell lines, A549 and H1299, overexpression of LIN28B and NRAS, after separate plasmid transfections, partly reduced the cell proliferation inhibitory effect of miR-4500 (Fig. 5D ).
Discussion
To our knowledge, this study may be the first report demonstrating the role of miR-4500 in NSCLC, or even in cancer. In this study, the correlation between miR-4500 expression and survival of NSCLC patients was revealed. High miR-4500 expression was correlated with high patient survival rate. Thus miR-4500 expression in NSCLC may be considered as a predictor for the prognosis of NSCLC. Previous study indicated that four miRNAs (hsa-let7a, hsa-miR-221, hsa-miR-372, and hsa-miR-182) could predict the stage and histological cells/well) were transfected with miR-4500 ASO or miR-NC ASO separately; the miR-4500 expression was assayed by qRT-PCR, 48h later; data were normalized to U6 small nuclear RNA; the miR-4500 expression in normal lung control was considered as 100%; data are mean ± s.d. of three separate experiments (A). After miR-4500 ASO transfection, the cells proliferation was assayed by the MTT assay at the indicted time points; data are mean ± s.d. of three separate experiments (B). The cell apoptosis rate was assayed by Annex V PI-FACS analysis after 48 h of miR-4500 transfection in MRC-5; the apoptosis rate in miR-NC ASO group was considered as 100%; data are mean ± s.d. of three separate experiments (C). *P<0.05. Putative targeted genes were predicted by TargetScanHuman, the binding site of putative targeted gene, and mutated site of LIN28B and NRAS are shown (A). The RL reporter plasmids (RLcontrol, RL-LIN28B, RL-mutated LIN28B, RL-NRAS, RL-mutated NRAS) and miR-4500 or miR-NC were co-transfected into HEK293 cells, along with a firefly luciferase reporter (pGL control) for normalization. Luciferase activity was measured after 48h. Then the ratio of RL activity of firefly luciferase activity in the miR-4500-treated group were calculated and compared with the ratio in the miR-NC group (which was considered as 100%); data are mean±s.d. of three separate experiments (B). Inverse correlation between the levels of miR-4500 and LIN28B or NRAS in NSCLC tissue samples (n=6); statistical analysis was performed using Pearson's correlation coefficient (C). A549 and H1299 cells (6×10 5 cells/ well) were transfected with miR-4500 or miR-NC (NC) separately; these cell were transfected with empty plasmid, or LIN28B or NRAS overexpression plasmid (pcDNA3.1-LIN28B or pcDNA3.1-NRAS) 12h later;
The NSCLC cell lines A549 and H1299 were chosen to assess the role of miR-4500 in NSCLC, because A549 and H1299 cells showed a lower miR-4500 level than other NSCLC cell lines. We investigated the NSCLC cells functions from two perspectives: up or down regulation of the miR-4500 level. We found that in A549 and H1299 cells, miR-4500 overexpression inhibited NSCLC proliferation and induced apoptosis, whereas down-regulation promoted proliferation and inhibited apoptosis. Interestingly, A549 cells expressed wild-type p53, while the H1299 cell line was p53-deficient. The TargetScan Bioinformatic algorithm predicted that p53 was a potential target of miR-4500 (data not shown). Our data indicated that after miR-4500 regulation, the A549 and H1299 cells exhibited a similar cellular behavior. Thus this discrepancy warranted further investigation.
We proved that in NSCLC, miR-4500 targeted the genes LIN28B and NRAS. Previous study showed that Lin28B transactivation is necessary for the Myc-induced let-7-mediated repression and proliferation [30] ; and c-Myc oncogenic transcription factor (Myc) broadly influences miRNA expression and in particular leads to widespread miRNA down-regulation [31] . Consequently, in NSCLC, it is possible that Myc caused the down-regulation of miR-4500, which led to the expression of LIN28B. This potential causal chain needs further investigation.
Obviously, all our mechanistic data came from in vitro experiment. Hence, whether miR-4500 overexpression inhibited NSCLC proliferation and induced apoptosis in vivo needs to be studied.
In conclusion, our data proved that down-regulation of miR-4500 promoted NSCLC cells proliferation by targeting LIN28B and NRAS. Our study revealed encouraging data which suggest the use of miR-4500 as a prognosis predictor and potential therapeutic target in NSCLC. However, there is a long way to clinically apply these findings. In the prospective studies, we plan to confirm the role of miR-4500 in NSCLC in vivo. Finding potential in vivo targets and ascertaining clinical safety warrant deeper study.
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